Integral Health Asset Management LLC Purchases 175,000 Shares of Bristol-Myers Squibb (NYSE:BMY)

Integral Health Asset Management LLC raised its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 100.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 350,000 shares of the biopharmaceutical company's stock after buying an additional 175,000 shares during the quarter. Bristol-Myers Squibb accounts for 1.7% of Integral Health Asset Management LLC's portfolio, making the stock its 18th largest position. Integral Health Asset Management LLC's holdings in Bristol-Myers Squibb were worth $19,796,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in BMY. Wealth Enhancement Advisory Services LLC lifted its position in shares of Bristol-Myers Squibb by 1.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 354,161 shares of the biopharmaceutical company's stock worth $18,324,000 after purchasing an additional 3,827 shares in the last quarter. Czech National Bank lifted its position in Bristol-Myers Squibb by 6.5% in the 4th quarter. Czech National Bank now owns 439,749 shares of the biopharmaceutical company's stock worth $24,872,000 after buying an additional 26,747 shares in the last quarter. Aprio Wealth Management LLC boosted its stake in shares of Bristol-Myers Squibb by 72.9% during the 4th quarter. Aprio Wealth Management LLC now owns 8,282 shares of the biopharmaceutical company's stock valued at $468,000 after buying an additional 3,493 shares during the period. Fiduciary Alliance LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $253,000. Finally, Trust Co. of Toledo NA OH increased its stake in shares of Bristol-Myers Squibb by 21.8% in the fourth quarter. Trust Co. of Toledo NA OH now owns 46,679 shares of the biopharmaceutical company's stock worth $2,640,000 after acquiring an additional 8,341 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

BMY stock traded up $1.60 during mid-day trading on Thursday, reaching $45.72. 27,423,080 shares of the stock traded hands, compared to its average volume of 13,260,604. The firm has a market capitalization of $93.04 billion, a PE ratio of -10.34, a P/E/G ratio of 2.07 and a beta of 0.39. The business has a 50-day moving average of $53.69 and a two-hundred day moving average of $56.06. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($4.40) EPS. As a group, equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.42%. Bristol-Myers Squibb's payout ratio is 92.88%.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.09% of the stock is currently owned by insiders.

Analyst Ratings Changes

BMY has been the subject of a number of research reports. UBS Group reduced their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.